2,848 AbbVie Inc. $ABBV Shares Sold by Patrick Mauro Investment Advisor INC.

Patrick Mauro Investment Advisor INC. decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 9.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 28,194 shares of the company’s stock after selling 2,848 shares during the period. AbbVie comprises approximately 2.4% of Patrick Mauro Investment Advisor INC.’s portfolio, making the stock its 9th biggest holding. Patrick Mauro Investment Advisor INC.’s holdings in AbbVie were worth $7,425,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. State Street Corp raised its holdings in shares of AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after buying an additional 23,991,451 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares in the last quarter. Legal & General Group Plc bought a new stake in AbbVie during the second quarter worth approximately $2,905,952,000. Finally, Deutsche Bank AG boosted its holdings in AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after buying an additional 1,241,587 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on ABBV. Argus upped their price target on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Barclays increased their price objective on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research report on Wednesday, October 21st. BMO Capital Markets set a $315.00 price objective on AbbVie in a research note on Wednesday, November 4th. Leerink Partners lifted their target price on AbbVie from $309.00 to $342.00 and gave the stock an “outperform” rating in a report on Monday, November 2nd. Finally, Piper Sandler boosted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $297.46.

Get Our Latest Stock Report on ABBV

AbbVie Price Performance

AbbVie stock opened at $295.18 on Monday. The firm’s 50 day simple moving average is $275.51 and its 200-day simple moving average is $240.91. The company has a market cap of $521.77 billion, a P/E ratio of 50.81, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.86 EPS. On average, analysts expect that AbbVie Inc. will post 13.98 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a $1.82 dividend. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is 119.10%.

About AbbVie

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Recommended Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.